Harrow, Inc. (HROW)
33.19
+0.09
(+0.27%)
USD |
NASDAQ |
Sep 25, 15:30
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.244B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -30.87% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 4.537 |
| Price to Book Value | 81.85 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 19.79 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 71.15% |
Profile
| Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN. |
| URL | http://www.harrow.com |
| Investor Relations URL | https://investors.harrow.com/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 10, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN. |
| URL | http://www.harrow.com |
| Investor Relations URL | https://investors.harrow.com/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 10, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |